Atrial fibrillation is a common heart condition characterized by a rapid, irregular heartbeat stemming from the heart's upper ...

ORLANDO, FL—(UPDATED) The Amplatzer Amulet device (Abbott) seals off the left atrial appendage (LAA) better than the Watchman 2.5 or Watchman FLX devices (Boston Scientific) in patients with atrial ...

SAN FRANCISCO -- Two mainstream devices for percutaneous left atrial appendage (LAA) closure continued to lead to similar clinical outcomes in the SWISS-APERO trial. Among patients randomized to the ...

(UPDATED) In patients undergoing left atrial appendage (LAA) occlusion, the Amplatzer Amulet device (Abbott) provides better closure as well as noninferior safety and effectiveness compared with the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Rates of patency and device-related thrombus were ...

Boston Scientific Corp. and Abbott Laboratories continue to parry over clinical trials comparing the latter’s Amplatzer Amulet with Boston Scientific’s Watchman in sealing the heart’s left atrial ...

Approximately 10.5 million Americans have atrial fibrillation (AFib), a condition that causes an irregular, often too fast, ...

SAN FRANCISCO — Thirteen months after percutaneous left atrial appendage closure (LAAC), outcomes did not differ whether closure was performed using the Amulet (Abbott Cardiovascular) or the Watchman ...

In the showdown between left atrial appendage (LAA) closure devices, the Amplatzer Amulet outperformed Watchman for peridevice leaks (PDL) in one trial longer term but not in another. At 12 months of ...

A new study finds clinicians are shifting away from the FDA-approved combination of warfarin and aspirin after left atrial appendage occlusion (LAAO) with the Watchman device and that adverse events, ...